Selecta Biosciences Inc:Selecta Biosciences Reports Second Quarter 2021 Financial Results And Provides Business Update.Q2 Revenue $19.7 Million.Q2 Revenue Estimate $7.1 Million -- Refinitiv Ibes Data.Selecta Biosciences - Cash, Cash Equivalents, Marketable Securities As Of June 30, 2021 Expected To Provide Runway Into Q3 Of 2023.Qtrly Basic Net Income Per Share Of $0.04.Qtrly Diluted Net Income Per Share $0.00.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments